Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2026-03-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（赵健梅）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2025 by an independent director of the company. It details the director's duties, attendance at board and shareholder meetings, opinions on major company matters, committee work, supervision of financial reports, appointment of auditors and senior management, communication with internal audit and accounting firms, and other governance-related activities. The content focuses on the independent director's role and activities rather than presenting full financial statements or comprehensive company financial performance. It is a governance-related report describing the independent director's duties and oversight for the year, which fits best under Board/Management Information (MANG) category rather than an Annual Report or Audit Report. The document length (4651 characters) and detailed narrative of director activities confirm it is a report by a board member rather than a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2026-03-27 Chinese
2025年度独立董事述职报告（孙钢宏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 from a specific independent director of the company. It details the director's activities, attendance at board and committee meetings, opinions on company matters, supervision of financial reports, communication with auditors, and other governance-related duties. The content focuses on the director's role and responsibilities rather than presenting financial data or audit results. It is a detailed report on board/management information, specifically about the independent director's duties and oversight during the year. It is not an annual report, audit report, or earnings release, nor is it a simple announcement or certification. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2026-03-27 Chinese
2025年度独立董事述职报告（曾令冰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2025 from a specific independent director of the company. It details the director's activities, attendance at board and committee meetings, opinions on major company matters, supervision of financial reports, internal controls, and compliance with laws and regulations. The content focuses on the director's duties and oversight rather than presenting financial statements or audit results. It is a formal report on the director's performance and responsibilities during the year, which aligns with Board/Management Information filings that report on governance and management activities. It is not an annual report, audit report, or earnings release, nor is it a simple announcement or certification. Therefore, the most appropriate classification is Board/Management Information (MANG).
2026-03-27 Chinese
董事津贴管理制度
Governance Information Classification · 95% confidence The document is titled '董事津贴管理制度' which translates to 'Board Director Allowance Management System'. It details the rules, standards, and payment methods for director allowances within the company. It includes governance-related policies about director compensation and management principles. There is no financial data, no report or announcement of financial results, no voting results, no legal proceedings, no capital changes, and no meeting materials. The content is focused on internal governance rules related to director compensation. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-27 Chinese
关于召开2025年年度股东会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2025 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting time, location, voting procedures, proposals to be discussed, and instructions for shareholders to participate. The document does not contain the actual annual report or financial statements but refers to the 2025 Annual Report and other related documents as proposals to be voted on at the meeting. The document length is 4229 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R).
2026-03-27 Chinese
第六届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the sixth board of directors' fourth meeting of Yunnan Watson Biotechnology Co., Ltd. It includes approvals of the 2025 annual report, financial reports, internal control evaluation, profit distribution plan, remuneration plans for directors and senior management, appointment of auditors for 2026, and other governance matters. The document repeatedly states that these reports and detailed contents are available on the designated disclosure website (巨潮资讯网) and that these resolutions will be submitted to the 2025 annual shareholders' meeting for approval. The document is not the annual report itself but a board meeting resolution announcement covering multiple governance and financial report approvals. It also includes remuneration and governance system amendments. This type of document fits best under Board/Management Information (MANG) as it announces board meeting decisions on management and governance matters, including approval of reports and remuneration, rather than the reports themselves. The document length (6974 characters) and content confirm it is a comprehensive board meeting resolution announcement, not a full annual report or other report type. Therefore, the classification is MANG with high confidence.
2026-03-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.